Lipid Nanoparticle-Encapsulated mRNA-Targeting CD19 for B and Plasma Cell Depletion in Autoimmune Diseases 2308376
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1427 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Yiming Zhou und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases driven by autoreactive B cells and plasma cells, leading to chronic inflammation and organ damage. Current therapies targeting B cells, such as anti-CD20 monoclonal antibodies, are ineffective in depleting long-lived plasma cells. This limitation highlights the need for novel therapeutic strategies to reset the immune system in these diseases.
Methods
We developed lipid nanoparticle-encapsulated mRNA (mRNab-LNPs) encoding anti-CD19 antibodies to deplete autoreactive B cells and plasma cells. mRNab-LNPs were administered intramuscularly to lupus and RA mouse models. We evaluated the therapeutic efficacy by assessing the depletion of CD19+ B cells and plasma cells, and the subsequent reduction in disease-related histopathological damage.
Results
Intramuscular injection of mRNab-LNPs in both lupus and RA mice led to high and sustained production of anti-CD19 antibodies. This resulted in significant depletion of circulating CD19+ B cells and tissue-resident plasma cells. Histopathological analysis showed reduced damage in the skin, kidneys, and joints of treated mice. Additionally, mRNab-LNPs exhibited favorable pharmacokinetics with prolonged antibody production and minimal systemic inflammatory response. Conclusion mRNab-LNPs effectively target and deplete both B cells and plasma cells in lupus and RA mouse models. These findings suggest that mRNab-LNPs offer a promising alternative to current therapies, providing a safer, more efficient approach to treating autoimmune diseases by resetting the humoral immune system. Funding Source This work was supported by the following grants: National Natural Foundation of China Grant (Nos. 81970632 and 52473328), Guangdong Science and Technology Department Grant (Nos. 2020B1212060018 and 2020B1212030004), Sun Yat-sen Pilot Scientific Research F Topic Categories Therapeutic Approaches to Autoimmunity (THER)
Zitieren
APA
Zhou, Y., Chen, J., & Guo, C. (2026). Lipid Nanoparticle-Encapsulated mRNA-Targeting CD19 for B and Plasma Cell Depletion in Autoimmune Diseases 2308376. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1427
Vancouver
Zhou Y, Chen J, Guo C. Lipid Nanoparticle-Encapsulated mRNA-Targeting CD19 for B and Plasma Cell Depletion in Autoimmune Diseases 2308376. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1427
BibTeX
@article{Zhou2026,
author = {Zhou, Yiming and Chen, Jinjin and Guo, Chipeng},
title = {Lipid Nanoparticle-Encapsulated mRNA-Targeting CD19 for B and Plasma Cell Depletion in Autoimmune Diseases 2308376},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1427}
}
EUVIMED